Infervision vs Lunit (2026)
Two Asian origin imaging AI companies that both reached international markets, with different centers of gravity. Lunit is cancer focused across chest radiograph and mammography, publicly listed, with the deeper evidence base in screening populations, which is the setting where a false positive rate multiplies across a large healthy denominator. Infervision spans lung nodule detection and chest interpretation across modalities with United States operations alongside its origin market, which gives an American buyer a closer support relationship. For a screening program, Lunit's evidence is the more relevant. For a health system wanting breadth across the imaging estate from one vendor, Infervision reaches further. Ask both for performance at your prevalence rather than in their validation cohorts.
- Its suite spans lung nodule detection and chest interpretation with United States operations alongside its origin market.
- Coverage extends across modalities rather than radiography alone, so one vendor reaches more of the imaging estate.
- For a buyer wanting an established American support relationship from a non Western vendor, that presence matters.
- Cancer detection across chest radiograph and mammography from a KOSDAQ listed company with regulatory footprints in multiple markets.
- The evidence base sits in screening populations, including a prospective Swedish study of 55,581 women, which is where both sensitivity and specificity bite.
- For a screening program, a portfolio built around cancer detection is a closer fit than general findings reading.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infervision and Lunit are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infervision | Lunit |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2013 |
| Headquarters | Beijing, China | Seoul, South Korea |
| Website | global.infervision.com | lunit.io |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Beijing based imaging AI company whose InferRead line detects findings on CT and radiographs (lung nodules on chest CT, chest abnormalities on radiographs, coronary stenosis on CTA, hemorrhage on head CT, chest fractures and pneumonia), alongside the InferOperate suite of 3D reconstructions for thoracic, liver and urologic surgical planning, InferCare for patient follow up and RECIST tumor assessment, and the InferScholar research and InferMatrix application platforms.
Source: AI Health Index, August 2026
Lunit is a cancer focused medical AI company founded in 2013, headquartered in Seoul and listed on KOSDAQ. Its radiology line is Lunit INSIGHT: MMG for 2D mammography (FDA cleared 2021), DBT for tomosynthesis (cleared 2023) and CXR for chest X-ray (CXR Triage cleared 2021).
Source: AI Health Index, August 2026
Questions buyers ask
How do Infervision and Lunit work with the EHR?
For Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) lists DICOM image input and reporting of results, with detection marks delivered as an overlay on the original CT. The product is reported in use at SimonMed, a US outpatient imaging provider, and in tuberculosis screening programs.
Lunit embeds its algorithms in imaging hardware and viewers through equipment and technology partners, more than 100 by its count, and also delivers through the cloud, so a customer can acquire the AI as part of a scanner or viewer purchase rather than as a separate integration project. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Infervision and Lunit priced and sold?
In Infervision's case, the company is reported to offer several pricing options rather than a single model, and its tuberculosis screening deployments were procured through international agencies by public tender, where the price is disclosed to the purchaser rather than published. The products are sold directly and through public procurement, but what drives the cost is not stated.
Lunit sells INSIGHT and its breast platform direct and through imaging equipment and viewer partners, so the software can arrive inside or alongside a scanner or viewer purchase. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Infervision and Lunit handle patient data?
With Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) says the software can run in the healthcare facility or on a cloud platform, and that cybersecurity and vulnerability analyses found it conforms to the cybersecurity requirements, a general assurance about the product.
In Lunit's case, the INSIGHT MMG FAQ says images from commercial sites are retained only for the duration of processing and are not used for retraining, that the models do not learn in real time, and that training data is biopsy proven material sourced through formal collaboration agreements. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
What evidence is published for Infervision and Lunit?
For Infervision, the company's research page lists more than 330 peer reviewed publications and conference abstracts, and the home page names none of them for a product sold. Deployment is reported at scale, including a US partnership with SimonMed and tuberculosis screening programs procured through international agencies in Eastern Europe and Central Asia and in Zimbabwe; the home page reports coverage of more than 30 countries.
An independent external evaluation in JAMA Oncology (Salim and colleagues, 2020) compared three commercial algorithms on a retrospective Swedish screening cohort, and Lunit's had the highest accuracy. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are non Western origin imaging vendors and the pattern this index records applies to both: regulatory effort follows market access while commercial assurance documentation is thinner, so ask for attestations and business associate terms explicitly. Findings counts are not comparable between vendors because each counts differently.
Prevalence in your own population determines the false positive burden more than published sensitivity does, and neither publishes performance stratified that way, which matters most in screening where the denominator is large and healthy.